2-羟基-5-硝基-N-苯基苯甲酰胺 | 2389-37-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-羟基-5-硝基-N-苯基苯甲酰胺
• 英文名称: 2-hydroxy-5-nitro-N-phenylbenzamide
• 英文别名: N-phenyl-2-hydroxy-5-nitrobenzamide；2-hydroxy-5-nitrobenzoyl aniline；2-hydroxy 5-nitrobenzanilide；2-hydroxy-5-nitro-N-phenyl-benzamide；2-hydroxy-5-nitro-benzoic acid anilide；2-Hydroxy-5-nitro-benzoesaeure-anilid
• CAS: 2389-37-9
• 化学式: C₁₃H₁₀N₂O₄
• 分子量: 258.233
• InChiKey: BZVYEQLTYLFTNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  95.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-羟基-5-硝基-N-苯基苯甲酰胺 在 溴 作用下， 生成 3-bromo-2-hydroxy-5-nitro-benzoic acid-(2,4-dibromo-anilide)
  参考文献：
  名称：

  Jadhav; Nerlekar, Journal of the Indian Chemical Society, 1952, vol. 29, p. 234,235

  摘要：

  DOI：
• 作为产物：
  描述：

  水杨酰苯胺 在 硝酸 、 溶剂黄146 作用下， 生成 2-羟基-5-硝基-N-苯基苯甲酰胺
  参考文献：
  名称：

  Huebner; Mensching, Justus Liebigs Annalen der Chemie, 1881, vol. 210, p. 342

  摘要：

  DOI：

文献信息

• PHOSPHONIUM COMPOUND, EPOXY RESIN COMPOSITION INCLUDING THE SAME AND SEMICONDUCTOR DEVICE PREPARED FROM THE SAME
  申请人：SAMSUNG SDI CO., LTD.

  公开号：US20160115184A1

  公开（公告）日：2016-04-28

  A phosphonium compound, an epoxy resin composition, a method of preparing a phosphonium compound, and a semiconductor device encapsulated with the epoxy resin composition, the compound being represented by Formula 1:

  一种磷铵化合物，一种环氧树脂组合物，一种制备磷铵化合物的方法，以及用环氧树脂组合物封装的半导体器件，该化合物由式子1表示。
• 鏻化合物、制备其的方法、包括其的环氧树脂组合物以及由其制备的半导体装置
  申请人：三星SDI株式会社

  公开号：CN105541914A

  公开（公告）日：2016-05-04

  一种鏻化合物、制备其的方法、包括其的环氧树脂组合物以及由其制备的半导体装置。鏻化合物由下式1表示，其中各基团如文中所限定。所述鏻化合物具有高储存稳定性，能够加速固化环氧树脂和在低温下固化环氧树脂，同时使包含所述化合物、环氧树脂、固化剂等的混合物的粘度改变降到最低，甚至在所要时间和温度范围内固化，从而确保在高温下固化之后获得的环氧树脂组合物不会由于流动性降低而展现出模塑产物的可模塑性、机械特性、电特性以及化学特性的任何劣化。[式1]
• <p>Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs</p>
  作者：Jens Hagenow、Stefanie Hagenow、Kathrin Grau、Mohammad Khanfar、Lena Hefke、Ewgenij Proschak、Holger Stark

  DOI：10.2147/dddt.s236586

  日期：——

  Background: Ligands consisting of two aryl moieties connected via a short spacer were shown to be potent inhibitors of monoamine oxidases (MAO) A and B, which are known as suitable targets in treatment of neurological diseases. Based on this general blueprint, we synthesized a series of 66 small aromatic amide derivatives as novel MAO A/B inhibitors.Methods: The compounds were synthesized, purified and structurally confirmed by spectroscopic methods. Fluorimetric enzymological assays were performed to determine MAO A/B inhibition properties. Mode and reversibility of inhibition was determined for the most potent MAO B inhibitor. Docking poses and pharmacophore models were generated to confirm the in vitro results.Results: N-(2,4-Dinitrophenyl)benzo [d] [1,3]dioxole-5-carboxamide (55, ST-2043) was found to be a reversible competitive moderately selective MAO B inhibitor (IC50 = 56 nM, K-i = 6.3 nM), while N-(2,4-dinitrophenyl)benzamide (7, ST-2023) showed higher preference for MAO A (IC50 = 126 nM). Computational analysis confirmed in vitro binding properties, where the anilides examined possessed high surface complementarity to MAO A/B active sites.Conclusion: The small molecule anilides with different substitution patterns were identified as potent MAO A/B inhibitors, which were active in nanomolar concentrations ranges. These small and easily accessible molecules are promising motifs, especially for newly designed multitargeted ligands taking advantage of these fragments.
• Synthesis and biological evaluation of N-aryl salicylamides with a hydroxamic acid moiety at 5-position as novel HDAC–EGFR dual inhibitors
  作者：Miao Zuo、Yue-Wen Zheng、She-Min Lu、Yan Li、San-Qi Zhang

  DOI：10.1016/j.bmc.2012.05.034

  日期：2012.7

  A novel series of N-aryl salicylamides with a hydroxamic acid moiety at 5-position were synthesized efficiently. Their activities against EGFR kinase and HDACs were evaluated. All compounds displayed inhibitory activity against EGFR and HDACs. The antiproliferative activities of synthesized compounds were evaluated by MTT method against human cancer cell lines A431, A549 and HL-60. Compound 1o showed the most potent inhibitory activity against A431 and A549. Compounds 1k and 1n exhibited higher potency against HL-60 than gefitinib and SAHA. N-Aryl salicylamides with a hydroxamic acid moiety at 5-position is another new HDAC-EGFR dual inhibitors. (C) 2012 Elsevier Ltd. All rights reserved.
• Light-sensitive para quinone diazides for making printing plates
  申请人：AZOPLATE CORP

  公开号：US02754209A1

  公开（公告）日：1956-07-10